# Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 2

Page: https://stenobird.com/podcast/neurology-podcast-635512/updates-on-btk-inhibitors-and-multiple-sclerosis-trials-part-2
Text version: https://stenobird.com/podcast/neurology-podcast-635512/updates-on-btk-inhibitors-and-multiple-sclerosis-trials-part-2.md
Podcast: [Neurology® Podcast](https://stenobird.com/podcast/neurology-podcast-635512)
Published: 2026-07-30T16:00:00+00:00
Episode link: https://neurology.libsyn.com/updates-on-btk-inhibitors-and-multiple-sclerosis-trials-part-2
Audio file: https://traffic.libsyn.com/secure/neurology/Neurology_Podcast_-_July_30th_2026_v2.mp3?dest-id=937793
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/neurology-podcast-635512/episodes/updates-on-btk-inhibitors-and-multiple-sclerosis-trials-part-2
Duration seconds: 1227

## Resource

In part two of this series, Dr. Shuvro Roy talks with Drs. Jiwon Oh and Amit Bar-Or about the latest developments in BTK inhibitors for MS, including safety signals, trial results, and future directions. For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting . Read more about the Fenebrutinib Trial . Disclosures can be found at Neurology.org .

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/neurology-podcast-635512/episodes/updates-on-btk-inhibitors-and-multiple-sclerosis-trials-part-2/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/neurology-podcast-635512/updates-on-btk-inhibitors-and-multiple-sclerosis-trials-part-2.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.